Community/Retail

Social media has allowed us to connect with generations of pharmacists and provide advice to students on a larger scale.

New trials show Pfizer’s Paxlovid (nirmatrelvir-ritonavir) speeds COVID-19 recovery in vaccinated patients, while hospitalization benefits fade.

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

Andel's direct-to-employer model partners with Eli Lilly and other pharma companies to offer flexible, insurance-free GLP-1 access that benefits employers, patients, and manufacturers.

The agency's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List signals that large-scale compounding of these agents has no regulatory future, and carries immediate implications for pharmacy practice.

The dextromethorphan-bupropion combination therapy targets NMDA and sigma-1 receptors, offering a first-in-class mechanism distinct from the only other approved agent for this indication.

Advanced therapy innovations are transforming cancer care but are outpacing delivery systems and community providers with specialty pharmacy support are the key to bridging the gap.

Coordinated pharmacist-led outreach, e-consults, and continuous glucose monitoring support improve diabetes outcomes, increase guideline-based therapy use, and impact total cost of care.

Cardinal Health’s 2026 Advanced Therapies Report found strong provider momentum for expanding advanced therapy administration into community settings.

Fran Gregory, PharmD, outlines the expanding landscape of advanced therapies and the pivotal role specialty pharmacies play in bringing these complex treatments to community-based providers and patients.

Integrated health plan–provider collaboration enables pharmacists to drive proactive diabetes management, improve adherence, and expand access to CGM and lifestyle support.

2026 dyslipidemia guideline updates highlight earlier risk-based lipid management, expanded biomarker use, and a growing pharmacist role in cardiovascular prevention.

Craig Beavers and Kyle Fischer debrief on key late-breaking cardiovascular trials from the 2026 American College of Cardiology Scientific Sessions.

Cannabis use is common among patients receiving medications for opioid use disorder and is associated with higher rates of anxiety and other comorbid symptoms.

Combining AI-driven insights with human-first outreach can overcome the emotional and behavioral barriers driving specialty medication nonadherence.

The FDA expands teplizumab-mzwv use to ages 1+ with stage 2 type 1 diabetes, detailing PETITE-T1D safety, EBV/CMV precautions, and pharmacist support to delay onset.

Two studies presented at the World Congress of Nephrology 2026 highlight nonpharmacological strategies that may help preserve kidney function in at-risk populations.

The once-weekly Saphnelo Pen offers adult patients with systemic lupus erythematosus a new, at-home alternative to monthly intravenous infusions, supported by robust phase 3 data.

Large real-world analysis supports potential renal and survival benefits of urate-lowering therapy in patients with chronic kidney disease and hyperuricemia.

The actions will support the development of psychedelic-based therapies for PTSD, depressive disorders, and substance use disorders.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.

This week's episode highlights a new executive order signed by President Trump, new expanded FDA approvals, and a conference roundup.

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

A cognitive neurologist outlines the current Alzheimer disease treatment landscape.

Pharmacists must remain in a constant state of readiness by implementing structured shortage management plans and guiding patients through access challenges as supply disruptions persist.

Extended data from ACHIEVE-4 reinforce the durability of oral GLP-1 receptor agonist therapy, with implications for long-term diabetes management and pharmacist-led care.

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.

AI is delivering immediate clinical value in neurology—from ambient scribes and clinical decision support to trial recruitment and medical education.